Myobloc (rimabotulinumtoxinB) will be considered for coverage when the following criteria are met:

**Cervical Dystonia (Spasmodic Torticollis)**

For **initial** authorization:
1. Member is 18 years old or older; AND
2. Medication must be prescribed by or in consultation with a neurologist or other specialist experienced with treating cervical dystonia; AND
3. Member has a documented diagnosis of moderate to severe cervical dystonia as evidenced by involuntary contractions of neck muscles, leading to abnormal movements or postures; AND
4. Symptoms affect quality of life and daily functions.
5. **Dosage allowed/Quantity limit:** Up to 5000 or 10,000 units every 12 to 16 weeks, divided among affected muscles.

*If member meets all the requirements listed above, the medication will be approved for 6 months.*

For **reauthorization**:
1. Member must be in compliance with all other initial criteria; AND
2. Chart notes show improved signs and symptoms (e.g. severity of abnormal head position, neck pain).

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*
Chronic Sialorrhea

For **initial** authorization:
1. Member is 18 years old or older; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
3. Member has diagnosis of chronic sialorrhea impacting quality of life for at least 3 months; AND
4. Member has tried and failed or has a contraindication to at least one anticholinergic drug (e.g. scopolamine, benzotropine, glycopyrrolate, amitriptyline).
5. **Dosage allowed/Quantity limit:** 1,500 Units to 3,500 Units, divided among the parotid and submandibular glands, every 3 months.

*If member meets all the requirements listed above, the medication will be approved for 6 months.*

For **reauthorization**:
1. Chart notes have been provided that show the member has improvement of signs and symptoms of disease.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.*

---

CareSource considers **Myobloc (rimabotulinumtoxinB)** not medically necessary for the treatment of the diseases that are not listed in this document.

---

**DATE** | **ACTION/DESCRIPTION**
--- | ---
08/06/2018 | New policy for Myobloc created. Age requirement removed. Criterion “no infection at proposed injection site” removed from Cervical Dystonia diagnosis. Age limitation removed from Cervical Dystonia; pain and abnormal head position requirements clarified and medications trial added.
06/09/2020 | Added new diagnosis of chronic sialorrhea and its criteria.
01/04/2021 | For sialorrhea, changed try 2 anticholinergics to try 1 anticholinergic. Added a reference.
08/10/2021 | Transferred to new template. Allowing additional specialists for cervical dystonia indication.
03/04/2022 | Annual review; no changes

References: